With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.624734-17-4,3-Methoxydihydro-2H-pyran-4(3H)-one,as a common compound, the synthetic route is as follows.
624734-17-4, Intermediate 21b3-Methoxy-tetrahydro-pyran-4-one* (1 g, 7.68 mmol), commercially available (R)-(+)-l- phenylethylamine (0.99 ml, 7.68 mmol) and Raney-Nickel (200 mg) in 10 ml of dry ethanol were stirred under a hydrogen atmosphere (5 bar) for 15 days. The reaction mixture was diluted with 20 ml of methanol and 20 ml of tetrahydrofurane, stirred for 15 minutes, filtered on a celite pad and concentrated under vacuum. The crude product was loaded on a SCX cartridge (50g). The cartridge was washed with methanol and the desired product was eluted with a 7 M solution of ammonia in methanol. The basic organic phase was concentrated under vacuum and the crude product was purified by flash chromatography(dichloromethane/methanol= 98/2%) to obtain 710 mg (3.02 mmol) of the desired product as single stereoisomer (diastereoisomeric purity confirmed and relative cis configuration assigned by NMR). GC/MS (method 3B) Rt = 35.04 min.
As the paragraph descriping shows that 624734-17-4 is playing an increasingly important role.
Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; EBEL, Heiner; FRATTINI, Sara; GIOVANNINI, Riccardo; HOENKE, Christoph; SCHEUERER, Stefan; WO2011/147772; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics